Angiotensin-II Receptor Blockers (ARB)

Property	Information
Drug Name	Angiotensin-II Receptor Blockers (ARB)
FDA Approval	Yes (for hypertension; repurposed for cancer studies)
Used for	Investigational use in glioblastoma for potential reduction of vasogenic edema and steroid-sparing effects
Clinical Trial Phase	Retrospective Studies
Clinical Trial Explanation	Not specified
Common Side Effects	Varies by specific ARB; can include dizziness, hypotension, and renal function alteration
OS without	Not specified
OS with	Not specified; studies have focused on steroid requirements and edema control
PFS without	Not specified
PFS with	Not specified; primary focus has been on edema reduction and potentially improved quality of life
Usefulness Rating	3
Usefulness Explanation	Not specified
Toxicity Level	2
Toxicity Explanation	Angiotensin-II Receptor Blockers, primarily used for high blood pressure, have been repurposed for cancer studies, specifically for reducing swelling around brain tumors and lowering the need for steroids. Common side effects can include dizziness, low blood pressure, and alterations in kidney function. However, these are generally mild and manageable, hence the relatively low toxicity rating. While these drugs have shown potential in improving some symptoms, their impact on tumor growth or survival rate is still under investigation.

Notes: ARBs, primarily used for hypertension, have shown potential in reducing steroid dose requirements and peri-tumoral edema in glioblastoma patients in retrospective studies. While no direct survival benefit has been observed, the reduction in steroid dosage and control of edema suggest a potential supportive role in glioblastoma management. Further research, including a randomized phase 3 trial in France, is exploring the impact of ARBs like losartan on glioblastoma treatment outcomes.

From Ben Williams Book: Not specified

Loading comments...